USRE32417E
Expired / Lapsed
US
⏱️ 0.0 years remaining
Radiolabeled antibody to anti-tumor associated antigen and process
Assignee: Summa Medical Corp
•
Filing: 1986-02-03
•
Granted: 1987-05-12
•
Expires: 2006-02-03
Abstract
Abstract Antibodies to human carcinoembryonic antigen (CEA), human alphafetoprotein (AFP) and/or to other anti-human tumor associated antigens (TAA) labeled with technetium-99m (Tc-99m) are administered to a human after the human has been administered anti-CEA, anti-AFP and/or other anti-TAAs, such as human melanoma-associated antigen, human neuroblastoma-associated antigen, human breast cancer-associated antigen, human ovary-associated antigen, human sarcoma-associated antigen, etc. The biodistribution of the labeled product composition accumulates at cancer sites, e.g., tumors that produce or express TAA, due to the affinity that the antibody has for the given tumor antigen. The accumulation at the tumor site(s) of a suitable amount of Tc-99m associated with the antibody allows detection via external scintigraphy and other means. Detection of the Tc-99m antibody composition by external scintigraphy permits localization and detection of tumors in vivo via a semi-noninvasive technique.
Inventors
- 👤 Scott W. Burchiel
- 👤 Buck A. Rhodes
- 👤 David R. Crockford
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 21:04
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K2123/00
Claims Analysis
Total Claims: 36
Claim 1
Independent Claim
75 words
A composition of matter comprising a radiolabeled antibody, said radiolabeled antibody either: (a) being directly reactive with .Iadd.an antibody to .Iaddend.a tumor associated antigen; or (b) being reactive with a second antibody which is directly reactive with said antigen, said reactivity with said second antibody either being direct or through a series of at least one third antibody, the last of said series being directly reactive with said second antibody, said radiolabel consisting of technetium-99m.
Claim 2
Dependent Claim
75 words
A composition of matter comprising a radiolabeled antibody, said radiolabeled antibody either: (a) being directly reactive with .Iadd.an antibody to .Iaddend.a tumor associated antigen; or (b) being reactive with a second antibody which is directly reactive with said antigen, said reactivity with said second antibody either being direct or through a series of at least one third antibody, the last of said series being directly reactive with said second antibody, said radiolabel consisting of technetium-99m.
Claim 3
Dependent Claim
11 words
The composition of claim 1 wherein said antigen is carcinoembryonic antigen.
Claim 4
Dependent Claim
10 words
The composition of claim 1 wherein said antigen is alphafetoprotein.
Claim 5
Dependent Claim
13 words
The composition of claim 1 wherein said antigen is human melanoma associated antigen.
Claim 6
Dependent Claim
12 words
The composition of claim 1 wherein said antigen is human neuroblastoma antigen.
Claim 7
Dependent Claim
14 words
The composition of claim 1 wherein said antigen is human breast cancer associated antigen.
Claim 8
Dependent Claim
13 words
The composition of claim 1 wherein said antigen is human carcinoma associated antigen.
Claim 9
Dependent Claim
13 words
The composition of claim 1 wherein said antigen is human ovary associated antigen.
Claim 10
Dependent Claim
13 words
The composition of claim 1 wherein said antigen is human sarcoma associated antigen.
Claim 11
Dependent Claim
27 words
The composition of any one of claims 1, 2, 3, 4, 5, 6, 7, 8 or 9 wherein said radiolabeled antibody is directly reactive with said antigen.
Claim 12
Dependent Claim
93 words
The process of detecting cancer cells and/or a malignant tumor in a human which comprises injecting into the human an antibody to a tumor associated antigen, subsequently injecting into the human the series of antibodies of claim 1 in the sequence said antibodies are produced with the last of said injected antibodies being said labeled antibody, the time between injections being sufficient to allow substantially all of said antigen and said antibodies not bound to said cells and/or tumor to be metabolized and monitoring the biodistribution of the radiolabeled antibody in said human.
Claim 13
Dependent Claim
16 words
The process of claim 11 wherein the tumor associated antigen is the composition of claim 2.
Claim 14
Dependent Claim
16 words
The process of claim 11 wherein the tumor associated antigen is the composition of claim 3.
Claim 15
Dependent Claim
16 words
The process of claim 11 wehrein the tumor associated antigen is the composition of claim 4.
Claim 16
Dependent Claim
16 words
The process of claim 11 wherein the tumor associated antigen is the composition of claim 5.
Claim 17
Dependent Claim
16 words
The process of claim 11 wherein the tumor associated antigen is the composition of claim 6.
Claim 18
Dependent Claim
16 words
The process of claim 11 wherein the tumor associated antigen is the composition of claim 7.
Claim 19
Dependent Claim
16 words
The process of claim 11 wherein the tumor associated antigen is the composition of claim 8.
Claim 20
Dependent Claim
16 words
The process of claim 11 wherein the tumor associated antigen is the composition of claim 9.
Claim 21
Dependent Claim
27 words
The process of any one of claims 11, 12, 13, 14, 15, 16, 17, 18 or 19 wherein said radiolabeled antibody is directly reactive with said antigen.
Claim 22
Dependent Claim
102 words
A diagnostic kit suitable for forming a composition useful in identifying a cancer cell and/or a malignant tumor which comprises a sterile package containing an antibody either: (a) being directly reactive with .Iadd.an antibody to .Iaddend.a tumor associated antigen; or (b) being reactive with a second antibody which is directly reactive with said antigen, said reactivity with said second antibody either being direct or through a series of at least one third antibody, a package sterilized reducing agent for technetium, and means for mixing the contents of said sterile package with said reducing agent for technetium-99m in a physiologically acceptable aqueous solution.
Claim 23
Dependent Claim
102 words
A diagnostic kit suitable for forming a composition useful in identifying a cancer cell and/or a malignant tumor which comprises a sterile package containing an antibody either: (a) being directly reactive with .Iadd.an antibody to .Iaddend.a tumor associated antigen; or (b) being reactive with a second antibody which is directly reactive with said antigen, said reactivity with said second antibody either being direct or through a series of at least one third antibody, a package sterilized reducing agent for technetium, and means for mixing the contents of said sterile package with said reducing agent for technetium-99m in a physiologically acceptable aqueous solution.
Claim 24
Dependent Claim
26 words
The kit of claim 21 wherein a physiologically acceptable reducing agent useful in reducing technetium (VII) to the technetium (IV) state is admixed with said protein.
Claim 25
Dependent Claim
14 words
The kit of claim 21 wherein said protein in said sterile package is lyophilized.
Claim 26
Dependent Claim
13 words
The kit of claim 22 wherein said protein and reducing agent are lyophilized.
Claim 27
Dependent Claim
31 words
The kit of claim 21 which includes a column of material for binding technetium in the IV state and of releasing said technetium when contacted with a solution of said antibody.
Claim 28
Dependent Claim
28 words
The kit of claim 23 which includes an ionic exchange resin for selectively removing pertechnetate ion from a solution containing pertechnetate ion from a protein labeled with technetium-99m.
Claim 29
Dependent Claim
22 words
The kit of any one of claims 21, 22, 23, 24, 25 or 26 wherein said tumor associated antigen is carcinoembryonic antigen.
Claim 30
Dependent Claim
21 words
The kit of any one of claims 21, 22, 23, 24, 25 or 26 wherein said tumor associated antigen is alphafetoprotein.
Claim 31
Dependent Claim
24 words
The kit of any one of claims 21, 22, 23, 24, 25 or 26 wherein said tumor associated antigen is human melanoma associated antigen.
Claim 32
Dependent Claim
23 words
The kit of any one of claims 21, 22, 23, 24, 25 or 26 wherein said tumor associated antigen is human neuroblastoma antigen.
Claim 33
Dependent Claim
25 words
The kit of any one of claims 21, 22, 23, 24, 25 or 26 wherein said tumor associated antigen is human breast cancer associated antigen.
Claim 34
Dependent Claim
24 words
The kit of any one of claims 21, 22, 23, 24, 25 or 26 wherein said tumor associated antigen is human carcinoma associated antigen.
Claim 35
Dependent Claim
24 words
The kit of any one of claims 21, 22, 23, 24, 25 or 26 wherein said tumor associated antigen is human ovary associated antigen.
Claim 36
Dependent Claim
24 words
The kit of any one of claims 21, 22, 23, 24, 25 or 26 wherein said tumor associated antigen is human sarcoma associated antigen.
References Cited (Backward Citations)
US3927193A
Cited
US4116776A
Cited
US4174385A
Cited
US4323546A
Cited
US4311688A
Cited
US4361544A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-05-11 | 1990-11-10 | 1991-05-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-05-11 | 1994-11-10 | 1995-05-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-05-11 | 1998-11-10 | 1999-05-12 | $7700.00 | Window Closed / Lapsed |